Home › Carcinoma uroteliale (a cellule transizionali) › New York › New York City
Studi clinici su Carcinoma uroteliale (a cellule transizionali) a New York City, NY
22 studi su Carcinoma uroteliale (a cellule transizionali) cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
In reclutamentoStudio osservazionale
- NYU Grossman School of Medicine, New York
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
In reclutamentoFase 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
In reclutamentoFase 1/2
- Icahn School of Medicine at Mount Sinai, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
In reclutamentoFase 1
- Columbia University Irving Medical Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
In reclutamentoFase 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
In reclutamentoFase 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
In reclutamentoFase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
In reclutamentoFase 1
- New York Cancer & Blood Specialists, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
In reclutamentoFase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- e altri 2
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
In reclutamentoFase 3
- Research Site, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
In reclutamento
- Integrated Medical Professionals, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
In reclutamentoFase 1
- MSK, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
In reclutamentoStudio osservazionale
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, New York
Studi su Carcinoma uroteliale (a cellule transizionali) in altre città
- Nashville, TN23 studi
- Houston, TX19 studi
- Dallas, TX18 studi
- Edison, NJ18 studi
- Los Angeles, CA17 studi
- Queens, NY15 studi
- Chicago, IL14 studi
- Arlington, VA12 studi
- Boston, MA11 studi
- San Antonio, TX11 studi
- Austin, TX10 studi
- Orange, CA10 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.